Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Novo Nordisk A/S ADR buy Morgan Stanley

Start price
€95.40
23.01.24 / 50%
Target price
€110.32
23.01.25
Performance (%)
-18.03%
End price
€78.20
24.01.25
Summary
This prediction ended on 24.01.25 with a price of €78.20. The price of Novo Nordisk A/S ADR has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -18.03%. Morgan_Stanley has a follow-up prediction for Novo Nordisk A/S ADR, but this time predicts that Novo Nordisk A/S ADR is a Sell. A total of €1.08 was paid as dividends for this prediction. Morgan_Stanley has 50% into this prediction
Performance without dividends (%)
Name 1w 1m 1y
Novo Nordisk A/S ADR -2.249% -2.249% -58.700%
iShares Core DAX® -4.597% -5.624% 19.813%
iShares Nasdaq 100 -2.857% -3.328% 6.800%
iShares Nikkei 225® -4.211% -5.242% 15.017%
iShares S&P 500 -2.037% -1.850% 2.096%

Comments by Morgan_Stanley for this prediction

In the thread Novo Nordisk A/S ADR diskutieren
Prediction Buy
Perf. (%) -18.03%
Target price 110.316
Change
Ends at 23.01.25

Novo Nordisk A/S (NYSE: NVO) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $120.00 price target on the stock.
Ratings data for NVO provided by MarketBeat

In the thread Trading Novo Nordisk A/S ADR
Prediction Buy
Perf. (%) -18.03%
Target price 110.316
Change
Ends at 23.01.25

Die von Morgan_Stanley gewählte maximale Laufzeit wurde überschritten

Current prediction by Morgan_Stanley for Novo Nordisk A/S ADR

Novo Nordisk A/S ADR

Start price
Target price
Perf. (%)
€45.95
29.09.25
€40.10
29.09.26
-10.99%
13:44